Screener Summaries Updates Institutions Sign In More Updates › Other Events › KMDA Other Events · Jul 13, 2026
Kamada Ltd. presented highlights from its CYTOGAM® study results at the 2026 ISHLT Annual Meeting KMDA Kamada Ltd
Kamada Ltd. presented highlights from its CYTOGAM® study results at the 2026 ISHLT Annual Meeting. The filing incorporates these study results as an exhibit to the report.
More from Kamada Ltd Kamada to report Q3 and nine-month financial results on November 9 Nov 2, 2026 Kamada launches Ustekinumab and Enoxaparin biosimilars in Israel, targeting $4M sales in 2026 Oct 6, 2026 Kamada Ltd. announced it obtained a tax ruling from the Israel Tax Authority regarding its previously declared cash… Sep 3, 2026 Kamada Ltd. declared a cash dividend of $0.17 per share, totaling approximately $9.8 million, consistent with its… Aug 17, 2026 Kamada Ltd. reported record-high first-half 2026 revenues of $100.2 million, a 13% year-over-year increase, with… Aug 12, 2026 All content on this site is for informational purposes only and does not constitute financial, investment, legal, or tax advice. Past performance is not indicative of future results. Always consult a qualified financial advisor before making investment decisions.
Financial data is obtained from public filings and third-party providers and is provided “as-is” without any guarantee of accuracy, completeness, or timeliness.
© 2026 go-intrinsic.com. All rights reserved.
